IMMUTEP Ltd
Business
Immutep Limited is a late-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company's lead candidate, eftilagimod alfa (efti), is a soluble LAG-3 fusion protein in registrational Phase III trials for non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer, with additional development in soft tissue sarcoma. The company operates through subsidiaries in the United States, Germany, France, and Australia, conducting clinical trials, manufacturing, and research activities.
Summary from 20-F filed 2025-10-24
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-61.43M |
| Total assets | $156.98M |
| Total liabilities | $13.35M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is IMMUTEP Ltd's CIK number?
IMMUTEP Ltd's SEC CIK number is 0001506184 (1506184). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find IMMUTEP Ltd's SEC filings?
All of IMMUTEP Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.